1. A polypeptide comprising 3 or more immuno-repeat units of surface exposed fragments of the major outer membrane protein (MOMP), wherein each immuno-repeat comprises an amino acid sequence which comprises the variable domain 1 (VD1) region of the MOMP chosen from any *Chlamydia* species serotype, wherein the amino acid sequences are optionally linearized.

2. The polypeptide according to claim **1**, wherein the immuno-repeats are homologous.

3. The polypeptide according to claim **1**, wherein the amino acid sequences comprising the VD1 region of the MOMP from any *Chlamydia* species serotype are placed next to each other.

4. The polypeptide according to claim **1**, wherein the immuno-repeats are heterologous.

5. The polypeptide according to claim **1**, wherein the MOMP from any *Chlamydia* species serotype is from *Chlamydia pneumoniae* or serotype D, E, F, G, Ia or J of *Chlamydia trachomatis*.

6. The polypeptide according to claim **1**, further comprising one or more of a variable domain 2 and a variable domain 3, each of the MOMP from any *Chlamydia* species serotype.

7. The polypeptide according to claim **1**, wherein the amino acid sequences are linearized.

8. The polypeptide according to claim **1**, wherein the amino acid sequences comprising the VD1 region of the MOMP from any *Chlamydia* species serotype are spaced with a linker.

9. The polypeptide according to claim **1**, comprising an amino acid sequence defined in formula II:

yy1-VD1-yy2 (Formula II)

wherein

VD1 is independently selected from SEQ ID NO. 1-6 or an amino acid sequence which has at least 80% sequence identity herewith SEQ ID NO: 1-6,

and

yy1 consists of

i) the amino acid sequence DAISMRVGYYGDFVFDRVLKTDVNKEFQMG (SEQ ID NO 7) or

ii) A subsequence of the amino acid sequence in i) said subsequence comprising 1-30 amino acid residues, starting with the C-terminal G in the amino acid sequence in i)

and

yy2 consists of

iii) The amino acid sequence NPAYGRHMQDAEMFTNAA (SEQ ID NO 8) or

iv) A subsequence of the amino acid sequence in iii) said subsequence comprising 1-18 amino acid residues, starting with the N-terminal N in the amino acid sequence in iii).

10. The polypeptide according to claim **1**, comprising the amino acid sequence selected from the group consisting of SEQ ID NO.: 9-14 and 45-48.

11. The polypeptide according to claim **1**, comprising 4 or more immuno-repeat units of surface exposed fragments of the major outer membrane protein (MOMP), wherein each immuno-repeat comprises an amino acid sequence which comprises the variable domain 1 (VD1) region of the MOMP chosen from any *Chlamydia* species serotype.

12. The polypeptide according to claim **1**, further comprising a moiety that facilitates export of the polypeptide when produced recombinantly, a moiety that facilitates purification of the fusion protein, or a moiety which enhances immunogenicity.

13. The polypeptide according to claim **12**, wherein the enhancer of immunogenicity is an additional T-cell target which is chosen from a *Chlamydia trachomatis* (Ct) antigen selected from the group consisting of CT043, CT004, CT414, CT681, and an immunogenic portion or fragment thereof.

14. The polypeptide according to claim **13**, comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 60-68.

15. The polypeptide according to claim **14**, comprising the amino acid sequence SEQ ID NO: 64.

16. A nucleic acid encoding the polypeptide according to claim **1**.

17. A pharmaceutical composition comprising the polypeptide according to claim **1** and one or more of a pharmacologically acceptable carrier, excipient, adjuvant, and immune modulator.

18. The pharmaceutical composition according to claim **17**, which comprises a pharmacologically acceptable adjuvant selected from DDA/TDB and alum.

19. The pharmaceutical composition according to claim **17**, which comprises a pharmacologically acceptable carrier in the form of a virus like particle.

20. A method for preventing, treating, or reducing the incidence of *Chlamydia* species infections in a subject, said method comprising administering an effective amount of a polypeptide according to claim **1** to said subject.

21. A method for preventing, treating, or reducing the incidence of *Chlamydia* species infections in a subject, said method comprising administering an effective amount of a nucleic acid according to claim **16** to said subject.

22. A method for preventing, treating, or reducing the incidence of *Chlamydia* species infections in a subject, said method comprising administering an effective amount of a pharmaceutical composition according to claim **17** to said subject.

* * * * *